Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The primary objectives of this study are to assess: (1) whether the combination of BP1001
plus venetoclax plus decitabine provides greater efficacy (Complete Remission [CR], Complete
Remission with incomplete hematologic recovery [CRi], Complete Remission with partial
hematologic recovery [CRh], than venetoclax plus decitabine alone (by historical comparison)
in participants with untreated AML that cannot or elect not to be treated with more intensive
chemotherapy; (2) whether BP1001-based treatment provides greater efficacy (CR, CRi, CRh)
than intensive chemotherapy (by historical comparison) in participants with
refractory/relapsed AML.